{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:32:28Z","timestamp":1791340348230,"version":"4.3.1"},"reference-count":53,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,4,29]],"date-time":"2010-04-29T00:00:00Z","timestamp":1272499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Histologic studies have shown B cell clusters in the subchondral bone marrow of the spine of patients with ankylosing spondylitis (AS). An immunotherapy targeting B cells in AS is therefore of interest. We undertook this study to examine the efficacy and safety of rituximab in patients with AS refractory to nonsteroidal antiinflammatory drugs in whom previous treatment with tumor necrosis factor \u03b1 (TNF\u03b1) blockers either had not been tried or had failed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase II clinical trial, 1,000 mg rituximab was administered intravenously at baseline and at week 2 in 20 patients with active AS. Ten of these patients had never received TNF blockers, and treatment with TNF blockers had failed in the other 10 patients. The primary end point was a 20% improvement in disease activity at week 24 according to the criteria of the Assessment of SpondyloArthritis international Society (an ASAS20 response).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy\u2010five percent of the patients were male, 90% were HLA\u2013B27 positive, their mean age was 39.7 years, and their mean disease duration was 16.8 years. Patients had active disease, defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score \u22654. While there was no clear response at week 24 in the group in whom TNF blockers had failed (30% had achieved an ASAS20 response, 10% had achieved an ASAS40 response, none had achieved partial remission according to the ASAS criteria, and none had achieved 50% improvement on the BASDAI [a BASDAI50 response] beyond an expected placebo response), we observed a good improvement in the TNF blocker\u2013naive group at week 24 (50% had achieved an ASAS20 response, 40% had achieved an ASAS40 response, 30% had achieved partial remission according to the ASAS criteria, and 50% had achieved a BASDAI50 response).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although rituximab does not seem to be effective in patients with AS that does not respond to TNF blockers, it had significant efficacy in TNF blocker\u2013naive patients. Therefore, further controlled trials with B cell\u2013directed therapies should be performed in TNF blocker\u2013naive AS patients in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.27383","type":"journal-article","created":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T08:41:46Z","timestamp":1272616906000},"page":"1290-1297","source":"Crossref","is-referenced-by-count":175,"title":["Different response to rituximab in tumor necrosis factor blocker\u2013naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty\u2010four\u2013week clinical trial"],"prefix":"10.1002","volume":"62","author":[{"given":"I.\u2010H.","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Heldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rudwaleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Listing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Appel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,4,29]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041137"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019174"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023176"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054098"},{"key":"e_1_2_8_7_2","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016386"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380407"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.2.135"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370709"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22060"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2035"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_2_8_18_2","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin A","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.074724"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.20"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.5.551"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.2.127"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016717"},{"key":"e_1_2_8_26_2","first-page":"862","article-title":"Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment","volume":"34","author":"Lukas C","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_2_8_28_2","first-page":"S228","article-title":"Long\u2010term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease\u2010modifying anti\u2010rheumatic drugs","volume":"54","author":"Emery P","year":"2006","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11325"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009749209095085"},{"key":"e_1_2_8_34_2","first-page":"71","article-title":"Intravenous high dose glucocorticoids in patients with ankylosing spondylitis","volume":"78","author":"Rumiantseva OA","year":"2006","journal-title":"Ter Arkh"},{"key":"e_1_2_8_35_2","first-page":"51","article-title":"The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis","volume":"53","author":"Richter MB","year":"1983","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780240521"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken362"},{"key":"e_1_2_8_38_2","first-page":"ii626","article-title":"Improvement of refractory ankylosing spondylitis in response to rituximab: a case report","volume":"67","author":"Schleenbecker SK","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_39_2","first-page":"iii626","article-title":"Lack of efficacy of rituximab in spondyloarthropathies: data of 8 patients prospectively followed in the French AIR (\u2018Auto\u2010Immunity and Rituximab\u2019) registry","volume":"68","author":"Nocturne G","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.01.023"},{"key":"e_1_2_8_41_2","first-page":"ii317","article-title":"Successful treatment of neutrophilic granulomatous dermatitis with rituximab in a patient with rheumatoid arthritis and spondylitis ancylosans: a case report","volume":"67","author":"Toussaint S","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23266"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017"},{"key":"e_1_2_8_44_2","first-page":"ii64","article-title":"Effectiveness and safety of adalimumab (humira) therapy after failure of prior TNF\u2010antagonists in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS)","volume":"66","author":"Burmester G","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f5e08d"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"e_1_2_8_47_2","first-page":"826","article-title":"Longterm clinical and immunological effects of anti\u2010CD20 treatment in patients with refractory systemic lupus erythematosus","volume":"35","author":"Lindholm C","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei080"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.079095"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02399.x"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21344"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken175"},{"key":"e_1_2_8_53_2","first-page":"2017","article-title":"Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations","volume":"35","author":"Seo P","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06602.x"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.27383","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.27383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T14:50:28Z","timestamp":1697035828000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.27383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,29]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1002\/art.27383"],"URL":"https:\/\/doi.org\/10.1002\/art.27383","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718524885.793498401","asserted-by":"object"}]},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,29]]}}}